Melanoma
Conditions
Brief summary
This is a medical chart review of ipilimumab treatment after nivolumab treatment in melanoma in Japan
Interventions
OTHERNon-Interventional
Non-Interventional
Sponsors
Ono Pharmaceutical Co. Ltd
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients \> 18 years of age or older * Diagnosis of advanced melanoma (unresectable/metastatic), alive or deceased as of date of data collection * Treated with ipilimumab between 31-Aug-2015 and 31-Mar-2017 before or after nivolumab treatment
Exclusion criteria
* Patients enrolled in any clinical trials at any time * Overlapping use of nivolumab and ipilimumab
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of ipilimumab treatment after nivolumab treatment | Approximately 19 months |
| Incidence of nivolumab treatment after ipilimumab treatment | Approximately 19 months |
| Duration of nivolumab treatment | Approximately 19 months |
| Duration of ipilimumab treatment | Approximately 19 months |
| Duration of interval between nivolumab treatment and ipilimumab treatment | Approximately 19 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall response rate (ORR) | Approximately 19 months | — |
| severity of treatment-related adverse events (AEs) | Approximately 19 months | severity of treatment-related adverse events (AEs)/adverse reactions (ARs) |
| best overall response rate (BORR) | Approximately 19 months | — |
| overall survival (OS) | Approximately 19 months | — |
| progression-free survival (PFS) | Approximately 19 months | — |
| incidence of treatment-related adverse events (AEs) | Approximately 19 months | incidence of treatment-related adverse events (AEs)/adverse reactions (ARs) |
Countries
Japan
Outcome results
None listed